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Background: It is recognised that modulations of the nuclear import of macromolecules have a role in changing cellular
phenotypes and carcinogenesis. We and others have noticed that aberrant subcellular localisation of DNA damage response
(DDR) proteins in breast cancer (BC) is associated with loss-of-function phenotype. This study aims to investigate the biological
and clinical significance of the nucleocytoplasmic transport protein karyopherin a-2 (KPNA2), and its role in controlling DDR
proteins subcellular localisation in BC.
Methods: A large (n¼ 1494) and well-characterised series of early-stage invasive BC with a long-term follow-up was assessed for
KPNA2 protein by using immunohistochemistry.
Results: KPNA2 expression was associated with the subcellular localisation of key DDR proteins that showed cytoplasmic
expression including BRCA1, RAD51, SMC6L1, gH2AX, BARD1, UBC9, PIAS1 and CHK1. High level of KPNA2 was associated not
only with cytoplasmic localisation of these proteins but also with their low/negative nuclear expression. Positive KPNA2 expression
was associated with negative oestrogen receptor and triple-negative phenotype. Survival analysis showed that KPNA2 was
associated with poor outcome (Po0.0001), but this effect was not independent of other prognostic variables.
Conclusions: This study provides further evidence for the complexity of DDR mechanism in BC, and that KNPA2 has a role in the
aberrant subcellular localisation of DDR proteins with subsequent impaired function.
The mechanisms of nucleocytoplasmic transport have been
reported to be associated with several cellular processes, such as
gene expression, progression of the cell cycle, apoptosis and signal
transduction (Chook and Blobel, 2001). Nuclear transport of
macromolecules is also essential for changing cellular phenotypes
throughout progression and malignant cell transformation (Poon
and Jans, 2005a). Karyopherin a-2 (KPNA2), an adaptor protein, is
a member of the karyopherin-a protein family that has a vital role
in nucleocytoplasmic transport. Previous studies have demon-
strated that karyopherin-a proteins bind to cargo proteins, which
contain a classical nuclear localisation signals (NLS), and import
macroproteins into the nucleus, hence the name importin (Gorlich
et al, 1994). However, the biological function of the different
members of karyopherin-a and their role as nuclear transport
proteins remain controversial. Some authors have indicated that
they mediate the nuclear import of proteins (Moroianu et al, 1995;
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Zannini et al, 2003; Nishinaka et al, 2004; Huang et al, 2013),
others have reported that KPNA2 mediates the export of response
molecules to the cytoplasm (Poon and Jans, 2005b). It is also
suggested that high nuclear accumulation of KPNA2 leads to
cytoplasmic retention of NLS-containing cargo proteins due to
defective import: the transporter factor KPNA2 is not recycled
back to the cytoplasm to transport the next karyophile into the
nucleus leading lack of ‘free’ KPNA2 to bind its cargo in the
cytoplasm (Gorlich and Mattaj, 1996). Nuclear localisation of
KPNA2 in cancer is thought to be due to cellular stress, and that
the nuclear retention of KPNA2 in response to cellular stress
suppresses the nuclear import (Stochaj et al, 2000a).
Previous studies have demonstrated that nuclear expression of
KNPA2 is associated with poor prognosis in patients with
oesophageal squamous cell carcinoma (Sakai et al, 2010b),
epithelial ovarian carcinomas (Zheng et al, 2010) and melanoma
(Winnepenninckx et al, 2006). In breast cancer (BC), expression of
KPNA2 is associated with features of aggressive behaviour such as
higher tumour grade and positive lymph node (Dankof et al, 2007;
Gluz et al, 2008), and poor outcome (Dahl et al, 2006). However,
the mechanism of action of KPNA2 and whether its bad prognostic
effect in BC is related to its direct function or through modulation
of other key driver molecules remain largely unknown. In previous
studies, we and others have noted that aberrant subcellular
localisation of key proteins including those involved in DNA
damage response (DDR) is associated with aggressive behaviour
and loss-of-function phenotype (Wilson et al, 1999; Lambie et al,
2003; Rakha et al, 2008; Alshareeda et al, 2012, 2013, 2014).
Cytoplasmic location of DDR proteins is also associated with
aggressive features in the prostate (Mitra et al, 2009). Subsequently,
we hypothesised that an active nucleocytoplasmic transport
mechanism contributes to modulation of the subcellular localisa-
tion of proteins related to BC development and progression. In this
study, KPNA2 protein is assessed in a large series of BC, and its
expression is correlated to the subcellular locations of a large panel
of relevant proteins and to BC clinicopathological features and
outcome.
MATERIALS AND METHODS
Study cohort. The study cohort was derived from the well-
characterised Nottingham Tenovus primary breast carcinoma
series. It comprised of 1249 unselected primary operable invasive
tumours from female patients presenting between 1989 and 1998.
To increase the number of oestrogen receptor (ER)-negative cases,
an additional 245 unselected primary operable BC, from patients
presenting between 1998 and 2003, were collected. As a control
group, a cohort of BC from BRCA1 germline mutation carriers
(n¼ 19) was included. Patients’ clinicopathological features were
obtained including age, menopause status, primary tumour size,
tumour type, histological grade, nodal status, lymphovascular
invasion and Nottingham Prognostic Index (NPI; Rakha et al,
2006; Alshareeda et al, 2013). Survival data were collected in a
prospective way including development of loco-regional and
distant recurrences and mortality. BC-specific survival (BCSS) is
defined as the interval from the date of primary surgery to the time
of death because of BC. Death owing to other causes is considered
as a censored event. Distant metastasis (DM) is defined as the
Table 1. Frequency of treatment received in the study
Treatment N (%)
Chemotherapy
No 1471 (82.3)
Yes 316 (17.7)
Endocrine treatment
No 1112 (62.2)
Yes 675 (37.8)
Endocrine and chemotherapy
No 816 (45.7)
Yes 971 (54.3)
Abbreviations: N¼ number of cases; No¼did not receive the treatment; Yes¼ received
treatment. According to the protocol used during the time of this study cohort, patients
with oestrogen receptor-positive tumours were not offered systemic therapy, if their
Nottingham Prognostic Index score wasr3.4, and therefore received no adjuvant therapy.
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Figure 1. Validation of KPNA2 primary antibody by western blotting.
Mixed lysates from MCF7 and MDA-MB-436 cell lines were used.
Figure 2. Nuclear expression of KPNA2 on invasive ductal carcinoma
no special type with cytoplasmic staining, which was not considered in
the scoring and analysis.
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interval from the date of primary surgery to the time of DM. Both
of these parameters were measured in months.
Tumour characteristics have been considered for patient’s
managements by selecting NPI and ER status (Rakha et al,
2006). Patients with NPI excellent prognostic group (score r3.4)
received no adjuvant therapy, but those patients with NPI 4 3.4
received Tamoxifen if ER positive (±Zoladex in case the patients
were pre-menopausal). On the other hand, classical cyclopho-
sphamide, methotrexate and 5-flurouracil were used if the patients
were ER negative and fit to receive chemotherapy. Patients with
grade II or III tumours and had node positive were given
prophylactic irradiation to the axilla following surgery (Blamey,
2002). Table 1 shows the frequency of the adjuvant treatment
received by the patients in the current study.
Data on the following biomarkers were available: ER, progester-
one receptor (PgR), HER2, DDR proteins (RAD51, PIAS1, BRCA1,
BARD1 and CHK1), basal markers cytokeratins (CK5, CK14 and
CK17), and the proliferation and cell cycle associated proteins
(Ki67 and P53). The immunoreactivity, scoring and categorisation
of these markers were defined in this study as previously described
(Rakha et al, 2006, 2009; Aleskandarany et al, 2012; Alshareeda
et al, 2012, 2013, 2014). In this series, HER2 was assessed using
immunohistochemistry (IHC) and dual-colour chromogenic in situ
hybridisation as previously published (Aleskandarany et al, 2012).
Ki67 labelling index was assessed on whole-tumour tissue sections,
and was expressed as the percentage of Ki67-positive cells among a
total number of 1000 malignant cells at high power magnification
Table 2A. Relationship between KPNA2 expression and
clinicopathological parameters in the whole series
KPNA2
Parameters Negative, N (%) Positive, N (%) v2 P-value
Age (years)
o50 205 (30.5) 299 (41.9) 20 o0.0001
X50 468 (69.5) 414 (58.1)
Size (cm)
p1.5 239 (35.6) 152 (21.6) 33 o0.0001
41.5 432 (64.4) 551 (78.4)
Stage
1 434 (64.4) 404 (56.9) 10 0.007
2 183 (27.2) 218 (30.7)
3 57 (8.5) 88 (12.4)
Grade
1 145 (21.5) 18 (2.5) 326 o0.0001
2 263 (39) 84 (11.8)
3 266 (39.5) 611 (85.7)
Tubules
1 40 (6.2) 7 (1) 104 o0.0001
2 251 (38.7) 133 (18.9)
3 357 (55.1) 565 (80.1)
Pleomorphism
1 15 (2.3) 3 (0.4) 220 o0.0001
2 295 (45.7) 77 (10.9)
3 335 (51.9) 624 (88.6)
Mitosis
1 287 (44.3) 57 (8.1) 316 o0.0001
2 141 (21.8) 85 (12.1)
3 220 (34) 563 (79.9)
NPI
Excellent 88 (13.1) 10 (1.4) 214 o0.0001
Good 164 (24.5) 36 (5.1)
Moderate 1 209 (31.2) 248 (35.4)
Moderate 2 132 (19.7) 225 (32.1)
Poor 61 (9.1) 136 (19.4)
Very poor 16 (2.4) 46 (6.6)
Tumour type
Invasive
ductal/NST
363 (55.3) 586 (82.9) 169 o0.0001
Lobular 47 (7.2) 11 (1.6)
Atypical
medullary
7 (1.1) 31 (4.4)
aMixed 206 (31.4) 68 (9.6)
bOther 34 (5.2) 11 (1.6)
Abbreviations: KPNA2¼ karyopherin a-2; NPI¼Nottingham Prognostic Index; NST¼ no
special type.
aLobular or tubular mixed breast cancers.
bMucinous, alveolar lobular, miscellaneous including metaplastic, adenoid cystic, spindle
and tubulolobular.
Table 2B. Relationship between KPNA2 expression and
clinicopathological parameters in patients who received
adjuvant therapy
KPNA2
Parameters Negative, N (%) Positive, N (%) v2 P-value
Age (years)
o50 83 (36.9) 142 (63.1) 7.67 0.006
X50 186 (48.4) 198 (51.6)
Size (cm)
r1.5 69 (60.5) 45 (39.5) 15.03 o0.001
41.5 201 (40.5) 295 (59.5)
Stage
1 97 (37.6) 161 (62.4) 11.64 0.003
2 142 (51.8) 132 (48.2)
3 31 (39.7) 47 (60.3)
Grade
1 21 (84.0) 4 (16.0) 97.69 o0.001
2 110 (74.3) 38 (25.7)
3 139 (31.8) 298 (68.2)
Tubules
1 4 (57.1) 3 (42.9) 23.42 o0.001
2 97 (59.5) 66 (40.5)
3 164 (37.7) 271 (62.3)
Pleomorphism
1 2 (66.7) 1 (33.3) 58.12 o0.001
2 100 (71.4) 40 (28.6)
3 162 (35.1) 299 (64.9)
Mitosis
1 88 (81.5) 20 (18.5) 117.77 o0.001
2 62 (65.3) 33 (34.7)
3 115 (28.6) 287 (71.4)
NPI
Excellent 2 (100) 0 48.07 o0.001
Good 20 (100) 0
Moderate 1 105 (51.2) 100 (48.8)
Moderate 2 92 (42.0) 127 (58.0)
Poor 46 (35.7) 83 (64.3)
Very poor 5 (14.7) 29 (85.3)
Tumour type
Invasive
ductal/NST
166 (37.4) 278 (62.6) 52.35 o0.001
Lobular 22 (78.6) 6 (21.4)
Atypical
medullary
2 (12.5) 14 (87.5)
aMixed 75 (65.8) 39 (34.2)
bOther 2 (100) 0
Abbreviations: KPNA2¼ karyopherin a-2; NPI¼Nottingham Prognostic Index; NST¼no
special type.
aLobular or tubular mixed breast cancers.
bMucinous, alveolar lobular, miscellaneous including metaplastic, adenoid cystic, spindle
and tubulolobular.
KPNA2 role in aberrant localisation and poor prognosis BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.165 1931
( 400) (Aleskandarany et al, 2012). All other markers were
assessed using IHC and TMA prepared sections.
This study was approved by Nottingham Research Ethics
Committee 2.
KPNA2 IHC. Immunohistochemistry was performed using the
Novolink Kit-polymer detection system (Leica, Newcastle, UK).
Primary antibody used was KPNA2 (clone Ab84440, Abcam Ltd,
Cambridge, UK) with a dilution of 1 : 400 and 60min incubation.
3-30Diam-inobenzidine tetrahydrochloride (Novolink DAB sub-
strate buffer plus) was freshly prepared and used as a chromogen.
The TMA sections were counterstained with haematoxylin for
6min (Alshareeda et al, 2012).
Immunohistochemical scoring. Two TMA cores (peripheral or
central) were evaluated from each tumour. Only immunostaining
of invasive cancer cells within the tissue cores was considered.
High-resolution digital images (Nanozoomer; Hamamatsu Photo-
nics, Welwyn Garden City, UK) scanned at  20 magnification
were used to facilitate the manual scoring of the TMA cores via
web-based interface (Distiller; Slidepath, Ltd, Dublin, Ireland).
Both intensity (scores 0–3 for negative, weak moderate and strong
expression, respectively) and percentage of KPNA2 expression
(0–100%) were assessed, and H-score was generated (a summation
of the percentage of area stained at each intensity level multiplied
by the weighted intensity to produce scores from 0 to 300). KPNA2
was categorised based on the frequency histogram distributions.
The cutoff point used was chosen based on the median H-score:
nuclear KPNA2 (negative/low o35 and positive X35 H-score).
Antibody specificity and reverse-phase protein microarray. To
ensure the specificity of the antibody and to confirm the expression
of KNPA2 in specific cell lines corresponding to molecular classes
of BC, western blotting and reverse-phase protein microarray
(RPPA) were performed as previously described (Mannsperger
et al, 2010; Aleskandarany et al, 2014; Negm et al, 2014). In this
study, two different cell lines were used: luminal phenotype MCF7
cell lines (characterised by positive expression of ER and BRCA1)
and MDA-MB-436 (ER- and EGFRþ ). Cells were grown in
RPMI1640 (Sigma Aldrich, Dorset, UK). For western blotting, anti
KPNA2 primary antibody was used in a dilution of 1 : 1000 and
incubated for 1 h at room temperature. The reaction was developed
using enhanced chemiluminescence substrate (GE Healthcare Life
Sciences, Buckinghamshire, UK).
For RPPA, in brief; KPNA2 antibody diluted 1 : 500 in diluent
with reducing background (DAKO). In addition, b-actin
(Sigma Aldrich), diluted 1 : 1000 in the same diluent, was used as a
housekeeping protein to control protein loading. Protein signals were
determined with background subtraction and normalisation to the
internal housekeeping targets using RPPanalyzer, a module within
the R statistical language on the CRAN (http://cran.r-project.org/).
Statistical analysis. SPSS 21.0 IBM statistical software (IBM
Corporation, New York, NY, USA) was used for different statistical
analyses. Categorical variables were analysed using w2-test. One-
way ANOVA was applied to compare the level of the expression
among different BC classes (by IHC or cell lines) using post hoc
test; Tukey. Associations with outcome were calculated using
Kaplan–Meier curves and log-rank test. A two-sided P-value of
o0.01 was considered statistically significant.
RESULTS
Expression of KPNA2 in invasive BC. The specificity of KPNA2
primary antibody was validated using western blotting as evident
by a single band at the correct protein size (Figure 1). KPNA2
showed nuclear staining, which ranged from negative/weak to
strong with no cytoplasmic or membranous staining observed
Table 3. Relationship between KPNA2 with other tumour
biomarkers
KPNA2
Parameters Negative, N (%) Positive, N (%) v2 P-value
ER
Negative 153 (23.9) 447 (63.8) 215 o0.0001
Positive 487 (76.1) 254 (36.2)
PgR
Negative 234 (37.7) 473 (71.5) 148 o0.0001
Positive 387 (62.3) 189 (28.5)
Triple negative
Negative 533 (85.3) 373 (55.8) 134 o0.0001
Positive 92 (14.7) 296 (44.2)
HER2
Negative 585 (90.4) 521 (76.6) 46 o0.0001
Positive 62 (9.6) 159 (23.4)
Ki67
Negative 306 (54.2) 105 (17) 180 o0.0001
Positive 259 (45.8) 513 (83)
CK18
Negative 44 (8.3) 109 (24.4) 47.7 o0.0001
Positive 486 (91.7) 337 (75.6)
RAD51
n c 35 (9.6) 14 (3.2) 38 o0.0001
nþ cþ 121 (33.3) 103 (23.4)
n cþ 187 (51.5) 313 (71)
nþ c 20 (5.5) 11 (2.5)
BRCA1
n c 119 (22.9) 218 (36.9) 96 o0.0001
nþ cþ 105 (20.2) 64 (10.8)
n cþ 107 (20.6) 209 (35.4)
nþ c 189 (36.3) 99 (16.8)
BARD1
n c 123 (21.1) 143 (21.5) 3 0.4
nþ cþ 46 (7.9) 67 (10.1)
n cþ 413 (71) 455 (68.3)
nþ c 0 1 (0.2)
CHK1
n c 39 (9.2) 17 (3.7) 27 o0.0001
nþ cþ 107 (25.2) 81 (17.7)
n cþ 259 (60.9) 348 (76.1)
nþ c 20 (4.7) 11 (2.4)
PIAS1
n c 88 (22.4) 50 (10.9) 45 o0.0001
nþ cþ 46 (11.7) 28 (6.1)
n cþ 239 (60.8) 373 (81.3)
nþ c 20 (5.1) 8 (1.7)
cH2AX
n c 9 (1.8) 11 (1.7) 47 o0.0001
nþ cþ 390 (76.5) 501 (78.2)
n cþ 38 (7.5) 100 (15.6)
nþ c 73 (14.3) 29 (4.5)
SMC6L1
n c 135 (23.3) 84 (12.8) 39 o0.0001
nþ cþ 277 (47.8) 365 (55.6)
n cþ 78 (13.4) 138 (21)
nþ c 90 (15.5) 69 (10.5)
UBC9
n c 175 (30.1) 157 (23.2) 57 o0.0001
nþ cþ 238 (40.9) 279 (41.3)
n cþ 104 (17.9) 217 (32.1)
nþ c 65 (11.2) 23 (3.4)
Abbreviations: c¼ cytoplasmic; ER¼oestrogen receptor; KPNA2¼ karyopherin a-2; N¼
number of cases; n¼ nuclear; PgR¼progesterone receptor; ‘ ’¼negative, ‘þ ’¼positive.
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(Figure 2). In sporadic BC, 51% (715 out of 1393) showed nuclear
expression compared with 17 out of 19 cases (90%) of the
hereditary BRCA1-mutated cases that showed KPNA2 expression
(Po0.001).
Association between KPNA2 and clinicopathological features.
Tables 2 summarises the association between KPNA2 and the various
clinicopathological features of BC in the whole series (Table 2A) and
in patients who received adjuvant therapy (Table 2B) summarises the
association between KPNA2 and the various clinicopathological
features of BC. KPNA2 protein expression was associated with
features of aggressive behaviour and poor prognosis including
younger patient’ age, larger tumour size, higher tumour grade (grade
III) with marked nuclear pleomorphism, lack of tubular formation
and high mitotic counts (Po0.0001).
Association between KPNA2 and molecular biomarkers. The
association between the KPNA2 and other tumour biomarkers are
summarised in Table 3. Figure 3 shows some examples of
subcellular cytoplasmic and nuclear expression of DDR proteins.
There was a significant association between KPNA2 expression
and lack of ER and PgR expression, triple-negative phenotype and
high expression of the proliferation marker Ki67 (Po0.0001).
Regarding DDR proteins, KPNA2 showed an association with
expression and subcellular localisation of markers involved in
homologous recombination pathway (SMC6L1, BRCA1 and
RAD51), DNA signal transducers (CHK1) and SUMOylation
(SUMO) markers (PIAS1; Po0.0001). KPNA2 expression was
associated with cytoplasmic localisation of these markers with a
nuclear-negative/cytoplasmic-positive phenotype (nuclear export
function).
When BC was classified into different molecular classes based
on BRCA1 and ER status, high KPNA2 expression was identified
in BRCA1-negative/ER-negative phenotype and in BRCA1-
mutated compared with BRCA1-positive/ER-positive classes
(Po0.0001; Figure 4). RPPA was used to evaluate the expression
levels of KPNA2 in the cell lines corresponding to BC molecular
classes used in this study. RPPA confirmed the IHC results of
KPNA2 and demonstrated lower levels of the expression of
KPNA2 in MCF7 cell lines (ERþ /BRCA1þ ) than in MDA-MB-
436 (ER /BRCA1 ) cell lines (Figure 5).
Expression of KPNA2 and patient outcome. Positive expression
of KPNA2 demonstrated an association with poorer outcome in
terms of shorter BCSS and shorter DM (Po0.0001; Figure 6A and
B respectively). When cases were subclassified according to grade
and ER status, KPNA2 maintained its association with outcome in
ER-positive group (Po0.001) but not in the ER-negative or in the
CHK1 SMC6L1
RAD51 BRCA1
BARD1 PIAS1
Figure 3. Immunostaining of key DDR proteins in BC showing subcellular localisation with nuclear and cytoplasmic expressions. Magnification
 20.
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different tumour grades. Multivariate Cox regression analysis
including stage, grade and size indicated that KNPA2 was not
independent predictor of outcome (Table 4).
DISCUSSION
Studying the localisation of proteins in several subcellular
compartments offers valuable insight into understanding state of
activation, interaction networks and the biological functions of
such proteins (Fu et al, 2010). Understanding the mechanisms
underlying aberrant subcellular location of proteins may help in
identification of potential targets and drug discovery (Chou and
Shen, 2008). The present study investigated the expression of
KPNA2 protein as a potential marker involved in the regulation
of subcellular location of key proteins in BC. A large panel of
biomarkers including DDR proteins was assessed. Although
biomarkers involved in DDR pathways are typically located and
function in the nucleus, some proteins such as BRCA1, BARD1,
PIAS1, RAD51 and CHK1 also show cytoplasmic expression as
detected by IHC. In previous studies, we and others noted that
cytoplasmic expression of these markers is associated with poor
prognostic features, such as higher grade and hormone receptor
negativity (Wilson et al, 1999; Lambie et al, 2003; Rakha et al, 2008;
Alshareeda et al, 2012, 2013, 2014). The significance and under-
lying mechanisms of this aberrant subcellular localisation remain
to be defined.
It has been reported that overexpression of the nucleocytoplas-
mic transport marker KPNA2 is associated with progression of BC
(Wang et al, 2005; Sotiriou et al, 2006). Gluz et al (2008) have
demonstrated that overexpression of nuclear KPNA2 in BCs was
significantly associated with aggressive tumour features such as
higher grade, negative hormone receptor status, HER2/neu
expression, shorter overall survival and DFI, although in this
study the effect of KPNA2 on patient’s outcome was not an
independent prognostic marker. However, the mechanism under-
lying the association between KPNA2 nuclear expression and
aggressive features in BC remains to be determined. To our
knowledge, this is the first study to investigate the role of KPNA2
in the subcellular localisation of key proteins related to BC
development and progression with particular emphasis on DDR
proteins using a large series including different molecular classes.
Our results indicate that KPNA2 nuclear expression is
associated with cytoplasmic and not the nuclear expression of
the studied DDR proteins. Although there is no direct evidence
that links this observation to an export function of KPNA2, it is
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Figure 4. KPNA2 protein level detected by IHC on TMA. Each bar
represents different class based on hereditary or sporadic BRCA1 and
ER status. Error bars represent mean (s.d.) was created on H-score
(range 0–300). A¼ sporadic cases (ER and BRCA1 ) vs sporadic cases
(ERþ and BRCA1þ ), Po0.0001; B¼ sporadic cases (ER and BRCA1 )
vs hereditary cases (ER ), P¼ 0.07; C¼ sporadic cases (ER and
BRCA1 ) vs hereditary cases (ERþ ), P¼ 0.97; D¼ sporadic cases
(ERþ and BRCA1þ ) vs hereditary cases (ER ), Po0.0001; E¼ sporadic
cases (ERþ and BRCA1þ ) vs hereditary cases (ERþ ), P¼0.14; and
F¼hereditary cases (ER ) vs hereditary cases (ERþ ), P¼0.9. ANOVA
test was used for each marker within the classes.
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Figure 5. KPNA2 protein levels detected by RPPA in MCF7 and MDA-MB-436 cells. For image of nitrocellulose slide spotted with different cell
lysates; the red fluoresence represents detection of b-actin, whereas green fluorsence for KPNA2. Images of scanned nitrocellulose slides printed
with extracted protein from cell lines and probed with the antibodies against the target proteins. Five two-fold dilutions of each sample were
printed in duplicate. Background was subtracted and the intensity of each spot was normalised to its corresponding b-actin level. Six experimental
replicates for each cell linewere used. Error bars represent mean (s.d.). As shown from the graph the expression level of KPNA2 was lower in MCF7
compared with MDA-MB-436 (Po0.05).
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more likely that high nuclear accumulation of KPNA2 leads to
increased amounts of DDR and other cargo proteins in the
cytoplasm due to defective import (Gorlich and Mattaj, 1996; Jans
et al, 2000). To get across the nuclear membrane and deliver its
NLS-containing cargo, KPNA2 may possibly bind importin
through its N-terminal IBB domain (Gorlich et al, 1996;
Nishinaka et al, 2004). In the nucleus, the components of these
complex, including the cargo, end up dissociated, thereby enabling
the recycling of KPNA2 returning to the cytoplasm (Moroianu
et al, 1996). Lack of ‘free’ KPNA2 to bind its cargo in the cytoplasm
may be responsible for its cytoplasmic retention. It was also
suggested that nuclear retention of KPNA2 in response to cellular
stress suppresses nuclear import (Stochaj et al, 2000b). It was also
reported that components of the nuclear transport machinery
appear to be differentially expressed in malignant cells with
alteration of nuclear import/export through different regulatory
mechanisms (Poon and Jans, 2005b).
Negative nuclear and positive cytoplasmic expression of
different markers such as RAD51, BARD1, BRCA1 CHK1 and
PIAS1 was highly associated with KPNA2, and the mechanism
inducing cytoplasmic localisation is unclear. Interestingly, in the
present study, it is likely that these proteins bind to or interact with
another marker, leading to change in their role when expressed in
the cytoplasm. Although, ions, small molecules and small proteins
(o20 kDa) are able to pass easily by diffusion through NPCs, the
macromolecules (440 kDa) with the appropriate signals are
restricted by NPCs (Weis, 2003; Wente and Rout, 2010). However,
in the present study, the exclusion of fusion proteins from the
nucleus to the cytoplasm is not size dependent, because some
markers have 440 kDa such as BRCA1 (B220 kDa), PIAS1
(71 kDa) and CHK1 (54 kDa), and this can be explained by
uncontrol travel of macromolecule from and to the nucleus owing
to a defect in NPCs.
In theory, as the nuclear import of the proteins investigated in
this study (DDR and SUMO markers) is dependent on interaction
with KPNA2, then the expression of KPNA2 is expected to
increase and have an effect on their nuclear localisation. Thus, high
levels of KPNA2 with other proteins in the cytoplasm may result in
their low expression in the nucleus. The expression of these
markers (such as RAD51) in the cytoplasm may have a role in the
poor prognosis of BC. In this study, there is a strong indication that
the poor prognosis of patients is largely associated with the
negative nuclear and positive cytoplasmic expression of any marker
tested, such as RAD51.
It has been proposed that BRCA1 is one of the proteins whose
subcellular distribution is controlled by NLS in direct interaction
with KPNA2, and therefore influences DNA repair and cell cycle
(Thakur et al, 1997; Narod and Foulkes, 2004). The observation
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Figure 6. Association between KPNA2 expression and BCSS (A) and DM (B). N, number of cases. Only patients who died from BC were
considered. Cutoff used for KPNA2 was the median of H-score, where negative/low o35 and positive X35.
Table 4. Cox regression analyses for predictors of outcome (BCSS and DM)
BCSS DM
95% CI 95% CI
Parameters P-value HR Lower Upper P-value HR Lower Upper
Tumour stage o0.0001 1.92 1.7 2.2 o0.0001 1.8 1.6 1.9
Tumour grade o0.001 1.87 1.5 2.3 0.034 1.2 1.01 1.3
Tumour size 0.001 1.07 1.03 111 0.206 1.03 0.98 1.09
KPNA2 0.221 1.15 0.87 1.4 0.227 1.2 0.92 1.4
Adjuvant therapy subgroup
Tumour stage o0.0001 2.05 1.7 2.5 o0.0001 1.8 1.6 1.9
Tumour grade o0.001 2.30 1.6 3.3 0.034 1.2 1.01 1.3
Tumour size 0.087 1.18 0.98 1.3 0.206 1.03 0.98 1.09
KPNA2 0.300 1.13 0.87 1.6 0.227 1.2 0.92 1.4
No adjuvant therapy subgroup
Tumour stage 0.006 1.64 1.1 2.3 0.001 1.6 1.2 2.1
Tumour grade o0.001 1.75 1.3 2.4 0.206 1.1 0.9 1.4
Tumour size o0.001 1.58 1.2 2.0 0.004 1.3 1.1 1.6
KPNA2 0.826 1.05 0.7 1.7 0.168 1.3 0.9 1.8
Abbreviations: BCSS¼breast cancer-specific survival; CI¼ confidence interval; DM¼distant metastasis; HR¼ hazard ratio; KPNA2¼ karyopherin a-2.
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that BRCA1 mutant deficiency of both NLSs can be observed in the
nucleus (Wilson et al, 1997; Huber et al, 2001) has resulted in the
identification of an alternative process in the importing of BRCA1
(Fabbro et al, 2002). The value of the two alternative pathways
continues to be identified. Although, in this study, KPNA2
expression is in association with cytoplasmic localisation of
BRCA1 and other key DDR such as RAD51, thereby leading to
dysfunction of these nuclear proteins with morphological and
immunophenotypical changes, which is similar to that seen in
tumours featuring ‘BRCA-ness’ phenotype. Although this could
suggest that KPNA2 IHC can be used as a surrogate marker for
BRCA-ness and subsequently be used as a predictive marker for
response to poly-ADP ribose polymerase (PARP) inhibitors, the
findings in this study do not provide sufficient evidence to support
this suggestion. Previous trials of PARP inhibitors showed
significant effect in patients with BRCA1 germline mutation, but
no such effect was noted in sporadic tumours even those showing
morphological and immunophenotypical similarities to BRCA1-
associated tumours (BRCA-ness) (Chen, 2011).
KPNA2 mediates the nucleocytoplasmic transport of some
tumour suppressors (Zannini et al, 2003; Nishinaka et al, 2004).
KPNA2 also controls both the nuclear localisation of the MRN
complexes with the formation of radiation-induced focus (Tseng
et al, 2005); therefore, the suppression of KPNA2 prevents the
double-stranded breaks (induced by ionising radiation), which will
lead to suppression of NSB-mediated DNA repair pathway. Tseng
et al (2005) have studied the role of NBS1 NLS in vivo using
immunofluorescence, and found that mutation in NBS1 resulted in
cytoplasmic redistribution and a decrease of IR-induced nuclear
focus formation of NBS1. Therefore, this finding together with the
fact that mutation of NLS disrupt the interaction with KPNA2
highlight the value of NBS1 NLS for its binding to KPNA2 and
therefore for NBS1 nuclear translocation (Teng et al, 2006).
Poor clinical outcome in BC is linked to overexpression of cell
cycle genes due to cell proliferation (Dai et al, 2005). Dai et al
(2005) have examined the molecular functions and biological
processes of 50 prognostic genes, including KPNA2 and E2F1, and
found that the majority of overexpressed genes in tumours with a
poor outcome are cell cycle-associated genes (Dai et al, 2005).
Interestingly, in the current study, there was a strong correlation
between KPNA2 expression and Ki67, and this may highlight the
essential role of KPNA2 in the proliferation signalling of BC. Sakai
et al (2010a) supported this finding but in oesophageal squamous
cell carcinoma. Therefore, the KPNA2 expression could possibly be
related to the induction of proliferation and the progression of BC.
However, further studies are mandatory to establish this hypo-
thesis. Despite the association between KPNA2 and outcome in
univariate analysis, it did not maintain its prognostic value when
other well-established prognostic variables were included. This can
be explained by the correlation between KPNA2 and other
prognostic variables such as histological grade, proliferation, stage
and ER status, and that the effect of KPNA2 on patient’ outcome is
dependent on these variables.
In this study, there was a strong correlation between KPNA2
and patient’s age; however, this was mainly a reflection of
difference in tumour grade and ER status. When the cohort was
stratified based on grade and ER status, the association between
KPNA2 and age became insignificant. In gastric adenocarcinoma
in which there is no correlation between age and grade or ER
status, Li et al (2013) did not find associations between KPNA2
expression and patient’ age. In this study, there was no correlation
between KPNA2 and BARD1. This can be explained by the
predominant cytoplasmic expression of this protein with very
small number of cases showing nuclear expression (9%).
Two different methods were used in this study to evaluate the
expression level of KPNA2. Interestingly, the RPPA results were in
accordance with those results obtained from IHC. The RPPA study
confirmed higher expression level in cells deficient in BRCA1
(MDA-MB-436) compared with the BRCA1-proficient cells
(MCF7).
In conclusion, KNPA2 nuclear expression is association
aggressive features in BC, and this may be related to aberrant
cytoplasmic localisation of key nuclear proteins. Further studies of
the impact of KPNA2 on the aberrant subcellular localisation of
DDR and other key proteins, and identifying alternative mechan-
ism for nuclear import of these proteins in BC, may identify novel
therapeutic targets.
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